MetLife SEC Filings

Form 144 notice for MetLife, Inc. (MET) reports a proposed sale of 333 shares of common stock, with an aggregate market value of $27,429.21, intended for sale on 10/01/2025 on the NYSE. The filing lists the securities' original acquisition dates: 114 shares purchased 06/20/2014 and 219 shares purchased 12/19/2014, both bought from GOLDMAN SACHS and paid in cash. The filing also discloses multiple sales of MetLife common stock by MetLife-related accounts during the past three months, including transactions on 07/28/2025, 07/31/2025 and 09/19/2025 with amounts and gross proceeds specified. Certain filer contact and CIK fields appear blank in the provided content.

MetLife, Inc. disclosed preliminary, unaudited estimates that its variable investment income for the quarter ended September 30, 2025 is expected to meet the company’s quarterly target of $425 million (pre-tax). This target is presented in the context of full-year 2025 guidance of approximately $1.7 billion (pre-tax) for variable investment income, which includes returns from private equity, real estate and other funds and prepayment fees. The company notes these figures are estimated and prepared in good faith on a basis consistent with prior periods but financial closing procedures are not complete and actual results could be materially different. These preliminary results are not substitutes for audited GAAP financial statements and are not necessarily indicative of future periods.

MetLife, Inc. (MET) filed a Form 144 proposing the sale of 269 shares of Common Stock through Bernstein Institutional Services on 09/19/2025, with an aggregate market value of $21,269.83. The shares were acquired on 06/20/2014 from GOLDMAN SACHS and payment was made in cash on 06/25/2014. The filing reports 665,026,054 shares outstanding for the issuer. The document also discloses multiple recent sales by MetLife-related accounts in June and July 2025, including 547 shares sold on 06/20/2025 and 1,024 shares sold on 06/27/2025, showing routine plan and separate-account transactions.

MetLife, Inc. (MET) filed a Form 144 reporting a proposed sale of 221 shares of common stock through Bernstein Institutional Services LLC with an aggregate market value of $17,474.47. The notice lists the company’s outstanding shares as 665,026,054 and an approximate sale date of 09/19/2025. The shares were originally acquired on 05/29/2015 in a purchase from Goldman Sachs with cash payment on 06/03/2015. The filing also discloses several recent sales by MetLife-related accounts between 06/20/2025 and 07/31/2025 totaling multiple transactions and varying gross proceeds.

MetLife, Inc. (MET) filed a Form 144 reporting a proposed sale of 17 shares of common stock through Bernstein Institutional Services LLC with an aggregate market value of $1,344.19. The filing lists the approximate sale date as 09/19/2025 and shows 665,026,054 shares outstanding. The 17 shares were acquired on 10/11/2021 in a purchase from Citigroup Global Markets with payment completed in cash on 10/13/2021. The filing also discloses prior sales by related MetLife accounts over the past three months totaling 2,628 shares for gross proceeds of $208,112.38. The notice includes the standard representation that the seller knows of no undisclosed material adverse information.

Form 144 filed for MetLife, Inc. (MET) reports a proposed sale of 64 shares of common stock through Bernstein Institutional Services on 09/19/2025 with an aggregate market value of $5,060.48. The filing states the shares were acquired on 12/17/2019 in a purchase from Bank of America and paid for in cash on 12/19/2019. The issuer has 665,026,054 shares outstanding per the filing. The notice also lists multiple sales by MetLife-related accounts between 06/20/2025 and 07/31/2025, totaling 2,628 shares for gross proceeds of $208,112.38. The filer certifies no undisclosed material adverse information.

MetLife disclosed receipt of an unsolicited mini-tender offer from Potemkin Limited to buy up to 10,000 shares of MetLife common stock at $53.00 per share, which the filing states is about 34.42% below MetLife's closing price of $80.82 on September 12, 2025. The shares subject to the offer equal approximately 0.00002% of MetLife's outstanding common stock as of August 31, 2025. MetLife does not endorse the offer, is not associated with Potemkin, and on September 15, 2025 issued a news release advising shareholders not to tender and explaining that shareholders who already tendered may withdraw prior to the offer's scheduled expiration at 5:00 p.m. ET on October 7, 2025. The news release is attached as Exhibit 99.1 and incorporated by reference.

Robert Glenn Hubbard, a director of MetLife, Inc. (MET), reported an acquisition on 09/09/2025 of 663 shares of MetLife common stock at a price of $79.29 per share. The filing shows the shares were credited through imputed reinvestment of dividends under the MetLife Deferred Compensation Plan for Non-Management Directors, meaning dividend payments that became payable were deferred and converted into additional deferred shares. After this transaction the reporting person beneficially owns 101,151 shares. The Form 4 was filed as a single reporting person filing and signed by an attorney-in-fact on 09/11/2025.

MetLife director Diana McKenzie reported a small insider acquisition under Form 4. On 09/09/2025 she received 158 shares of MetLife common stock at an imputed price of $79.29 through reinvestment of dividends under the MetLife Deferred Compensation Plan for Non-Management Directors. After the transaction her beneficial ownership is reported as 22,223 shares held directly. The Form 4 was filed as a single reporting person filing and signed on behalf of the reporting person by an attorney-in-fact on 09/11/2025.